A randomized, double-blind, controlled study of NGX-4010 [capsaicin] for the treatment of postherpetic neuralgia

Trial Profile

A randomized, double-blind, controlled study of NGX-4010 [capsaicin] for the treatment of postherpetic neuralgia

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Jan 2009

At a glance

  • Drugs Capsaicin (Primary)
  • Indications Neuropathic pain; Postherpetic neuralgia
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Jan 2009 Results were published in the December 2008 print edition of The Lancet Neurology, according to a NeurogesX media release.
    • 05 May 2007 Interim results have been reported.
    • 24 Jul 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top